MCH sells Lenitudes, invests in Atrys

The GP has reinvested in the combined group, becoming a relevant shareholder in Atrys.

With the acquisition of Lenitudes, Atrys intends to boost its expansion in the Portuguese radiotherapy market, while further consolidating its presence in Spain and the rest of Europe. This acquisition follows the purchase of AxisMed, a Brazilian company acquired by Atrys in October.

In addition, the integration of Lenitudes will allow Atrys to introduce its online diagnostics service in Portugal and will complement its offering.

MCH acquired a 66.5% stake in Lenitudes via its €250m MCH Private Equity Fund III in January 2014.

Company
Established in 2014 and headquartered in Santa Maria da Feira, Lenitudes is a provider of radio-diagnosis, nuclear medicine, radiotherapy, chemotherapy and clinical oncology services.

The company operates five radiotherapy and oncology centres located across Portugal.

People
MCH Private Equity – José María Muñoz (founding partner).
Atrys Health – Santiago de Torres (president).

Advisers
Vendor – Garrigues (legal).
Acquirer – Pinsent Mason (legal); Norgestión (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Expansion
• Southern Europe
• Healthcare
• MCH Private Equity
• Portugal
• Spain